Telehealth Language Intervention for Children With Autism Ages 2-4 Years

Sponsor
Weill Medical College of Cornell University (Other)
Overall Status
Completed
CT.gov ID
NCT04675580
Collaborator
(none)
14
1
2
18.7
0.7

Study Details

Study Description

Brief Summary

The main goal of this intervention is to increase caregivers' use of interactive play and communication strategies to improve the child's early sentence development using telemedicine and video-based feedback.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Toy Talk
N/A

Detailed Description

Record was updated 11/2/2021 to include more detailed information about outcome measure time points. Specifically, secondary outcome measures will be collected more frequently over the course of the study (i.e., at baseline [before starting intervention], immediate follow-up [week 12], and long-term follow-up [3 months after intervention] assessments). No changes were made to outcome measures or how they are operationalized.

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Tele Toy Talk: Telehealth Language Intervention
Actual Study Start Date :
Dec 23, 2020
Actual Primary Completion Date :
Jul 15, 2022
Actual Study Completion Date :
Jul 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tele Toy Talk

Caregivers of child participants receive 1-hour of telemedicine featuring parent-mediated naturalistic developmental behavioral intervention weekly for 10 weeks.

Behavioral: Toy Talk
Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.

No Intervention: Multiple Baseline

Prior to receiving the intervention, participants will be randomized into one of three baseline conditions: a three-, four-, or five-week baseline period. At each weekly baseline session, caregivers will record the Tele-BOSCC (see Outcomes Measures section).

Outcome Measures

Primary Outcome Measures

  1. Change in number of unique combinations of subjects and verbs - caregiver [Baseline (Before starting intervention); Week 4; Week 8; Week 12]

    Number of unique combinations of subjects and verbs used by the caregiver at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

  2. Change in number of unique combinations of subjects and verbs - child [Baseline (Before starting intervention); Week 4; Week 8; Week 12]

    Number of unique combinations of subjects and verbs used by the child at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

  3. Change in caregiver mean length of utterance [Baseline (before starting intervention); Week 4; Week 8; Week 12]

    Mean length of utterance used by caregiver at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

  4. Change in child mean length of utterance [Baseline (before starting intervention); Week 4; Week 8; Week 12]

    Mean length of utterance used by child at baseline, intervention midpoint, and post-evaluation. This will be calculated by transcribing 12-minute language samples from the BOSCC using Systematic Analysis of Language Transcripts (SALT) software.

  5. Change in Brief Observation of Social Communication Change (BOSCC) scores [Baseline (before starting intervention); Week 4; Week 8; Week 12]

    Child's scores on the Brief Observation of Social Communication Change (BOSCC) at baseline, intervention midpoint, and post-evaluation. BOSCC scores are not linear. Each item is rated on a 6-point scale from 0 (abnormality is not present) to 5 (abnormality is present and significantly impairs functioning).

Secondary Outcome Measures

  1. Change in scores on the Observation of Spontaneous Expressive Language (OSEL) - baseline [Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention)]

    Child's scores on the Observation of Spontaneous Expressive Language at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). Scores on the OSEL are not linear. Scores range from 0 to 3, with higher scores indicating more impairment.

  2. Change in scores on the Vineland-3 [Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention)]

    Scores on the Vineland-3 at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The Vineland-3 provides norm-referenced scaled scores for 11 skill areas (M = 10; SD = 3) as well as standard scores (M =100, SD = 15) for three adaptive domains.

Other Outcome Measures

  1. Change in scores on the Acceptance and Action Questionnaire, Second Version (AAQ-II) [Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).]

    Caregiver scores on the Acceptance and Action Questionnaire, Second Version (AAQ-II) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after end of intervention). Items are rated on a Likert-type scale of 1 through 7, and scores range from 7 to 49.

  2. Change in scores on the Emotion Regulation Questionnaire (ERQ) [Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).]

    Caregiver scores on the Emotion Regulation Questionnaire (ERQ) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The ERQ is a 10-item scale with each item consisting of a 7-point Likert-type scale ranging from 1 to 7.

  3. Change in scores on the Caregiver Strain Questionnaire - Short Form 7 (CSQ-SF 7) [Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).]

    Scores on the Caregiver Strain Questionnaire - Short Form 7 (CSQ-SF 7) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The CSQ-SF7 contains seven items, with response options on a five-point Likert-type scale.

  4. Change in scores on the Parent Stress Index-4th Edition (PSI-4) [Baseline (before starting intervention); Week 12; Follow-up assessment (3 months after end of intervention).]

    Scores on the Parent Stress Index (PSI-4) at baseline, post-evaluation, and long-term follow-up evaluation (3 months after ending intervention). The PSI-4 is a 120-item inventory that provides two domain scores that are quantified using T scores (mean of 50; standard deviation of 10).

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 4 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of autism spectrum disorder (ASD) and/or communication disorder

  • Child speaks at least 50 single words or uses emerging word combinations

  • Caregivers have Internet availability from their home

Exclusion Criteria:
  • Child speaks using complex sentences

  • Child is not within 2 to 4 years of age at time of enrollment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Autism and the Developing Brain/New York-Presbyterian Hospital White Plains New York United States 10605

Sponsors and Collaborators

  • Weill Medical College of Cornell University

Investigators

  • Principal Investigator: So Hyun Kim, Ph.D., Weill Medical College of Cornell University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT04675580
Other Study ID Numbers:
  • 21-03023432
  • 19-07020518
First Posted:
Dec 19, 2020
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2022